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With this commentary we would like to raise some issues that emerge as a result of recent evolutions 
in the burgeoning field of human cells, tissues, and cellular and tissue-based product (HCT/P) 
transplantation, and this in the light of the current EU regulatory framework. This paper is intended as 
an open letter addressed to the EU policy makers, who will be charged with the review and revision of 
the current legislation. We propose some urgent corrections or additions to cope with the rapid 
advances in biomedical science, an extensive commercialization of HCT/Ps, and the growing 
expectation of the general public regarding the ethical use of altruistically donated cells and tissues. 
Without a sound wake-up call, the diverging interests of this newly established ‘healthcare’ industry 
and the wellbeing of humanity will likely lead to totally unacceptable situations, like some of which 




Since the late 90s, the field of HCT/P transplantation is booming and the market value of some 
replacement parts such as bone and heart valves has been identified as very attractive. 
However, some ethical and safety scandals emerged such as non-consented procurement, inadequate 
testing, inaccurate or false donor files, irresponsible allocations and illegal trafficking of HCT/Ps. 
Hearings, lawsuits, convictions, resignations and the shut down of Tissue Establishments (TEs) 
followed. Mediatized cases such as the ‘France Hypophyse scandal’1, the ‘New York body-snatching 
ring’2 and the ‘Alder Hey organ retention scandal’3 drew public attention and questioned the adequacy 
of the regulatory framework that governed the HCT/P industry4.  
 
 
Introducing the EU legislation 
In 2004 the European Commission (EC) issued the EU Cells and Tissue Directives (EUCTDs). These 
directives were designed to assure harmonized and high standards of Quality and Safety (QS) for the 
donation, procurement, testing, processing, preservation, storage and distribution of human cells and 
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tissues, to facilitate their cross-border movements and to ensure availability in the EU. In 2007, the 
EUCTDs were supplemented with a regulation on Advanced Therapy Medicinal Products (ATMPs), 
including human tissue engineered and human somatic cell products, with additional requirements. 
This regulation should allow free movement of ATMPs within the EU market, better patients’ access 
to ATMPs, the highest level of health protection for patients, EU competitiveness in a key 
biotechnology area and growth of an emerging industry. These advanced therapies will transform 
treatment and prognosis of a number of diseases (e.g. myocardial infarct and Alzheimer) and thus hold 
huge potential for both patients and the industry. In the ATMP field, the major players are not large 
pharmaceutical companies, but rather small end medium-sized enterprises or (university) hospitals. 
With the EUCTDs and the ATMP regulation the EC did, however, introduce a series of expensive 
requirements and pharmaceutical industry standards, like Quality Management System (QMS) and 
guidance similar to Good Manufacturing Practices (GMP), into the field of HCT/P transplantation. For 
HCT/Ps that are classified as ATMPs, full blown GMP – which implies production in cleanrooms – is 
imposed. Suddenly the HCT/P field is confronted with practices and systems previously only required 




The EUCTDs were meant to facilitate cross-border movements of HCT/Ps. The heterogeneous 
transposition of the EUCTDs into EU Member State laws resulted in a patchwork of technical 
standards. At first sight, a setting that will not facilitate transnational movements. However, the 
unequal distribution of wealth and the lack of a global ethical framework5 seem to create exploitation 
opportunities that are considered by some as unethical and solely based on profit-maximizing (cross-
border) movements of HCT/Ps. Surely, where you have different regulations, you will have trading 
across the borders. Some TEs even considered using the international shipping legislation to bypass 
divergent national HCT/P regulations. For example, the world’s largest sperm bank explored the 
deployment of so-called ‘sperm ships’ flying Danish flags in the international waters based just 
outside the UK border to (legally) circumvent the strict UK In Vitro Fertilization (IVF) regulation6. 
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Unfortunately, cross-border movements of HCT/Ps strictly for (altruistic) medical reasons – as 




The EUCTDs were meant to secure safe procurement of human cells and tissues across Europe. In 
addition, the ATMP regulation intended to introduce certain requirements for manufacturing. 
However, it is clear that HCT/Ps are not only characterized by their manufacture, but also by their 
source, which gives rise to complex issues that are unusual for (ATMP) regulators and inspectors used 
to handling conventional source materials7. 
The main caveat is related to the limited supply of starting materials (donors) in respect of all types of 
human cells and tissues. This creates problems in view of companies who are put under pressure to 
maximize their profits as much as possible. For example, according to CNN Money, the product 
Alloderm (a skin substitute derived from human cadaveric skin) earned LifeCell the 16th place on 
FORTUNE's 100 Fastest-Growing Companies list in 2004 and prompted them to recommend 
LifeCell's stock8. One potential hitch was reported: ‘raw material’ (human donor skin) supply 
constraints. In addition, there are certain unethical practices by some companies that try to get 
increasing amounts of raw tissues, preferably at a low price. International brokers and unprofessional 
middlemen are known to supply human organs, cells and tissues, obtained in low-income countries 
without self-sufficiency, basically located in Africa, Asia, eastern Europe and South America, to the 
powerful industry in human tissues1, 9-12. In this way, certain TEs in rich western European, North 
American and Asian countries obtain large amounts of raw materials for small fees, which in turn 
make welcome additions to salaries in countries with low pay levels. Supporters of these practices 
claim that these fees are used to develop the health care systems in these low-income countries. 
However, there are indications that in some cases these fees were transferred directly to the personal 
accounts of middlemen. The local health care system mostly remains deprived of the transplantation of 
the exported types of tissues. Apart from ethical and in some cases legal problems, these activities 
have posed major risks of transmission of diseases. An example happened in France in the late 80s. 
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While the US and Britain halted the distribution of human growth hormone (in 1985) after it was 
discovered that people had died due to Creutzfeldt-Jakob disease after being given the product, which 
at that time was extracted from pituitary glands removed from corpses, doctors in France continued to 
use the hormone for several years, treating thousands of children. Nearly 60% of the deaths worldwide 
caused by that treatment were in France. The media raised a thorny issue. Part of the pituitary glands 
were removed outside France, in Bulgaria, allegedly through a network of non-medical staff that took 
the pituitary glands from corpses in morgues for cash payments of a few francs per gland. According 
to media reports, the glands were often removed with crude instruments, such as coat hangers, through 
the nostrils of the corpse. As a result, contaminated brain tissue was sometimes also taken with the 
gland and was present in the extracted growth hormone1. 
In contrast to organs, there is no scarcity in tissues, at least in general terms. Tissue shortage is mostly 
due to organizational problems and/or a lack of human and material resources9. What is then the 
answer to the key question ‘why do some TEs in rich countries prefer to procure human organs, cells 
and tissues in developing countries’? Are regulatory requirements in developing countries less 
stringent, procurement costs lower, rights of donor families less founded, or corruption in healthcare 
more widespread?  
 
 
(Un)reasonable processing fees 
The EUCTDs aimed at regulating the processing of human cells and tissues at a European level. In the 
EU (as is the case in the US as well) it is illegal to buy and sell human cells and tissues, even if they 
are procured outside Europe. The principle that it is not permissible for the human body or its parts as 
such to give rise to financial gain was established in Article 21 of the 1997 Council of Europe 
Convention of Human Rights and Biomedicine. Nevertheless, human cells and tissues are sold across 
borders worldwide, as it is not illegal to compensate hospitals, coroners and morgues for reasonable 
costs and charge ‘reasonable fees’ for the processing rather than the direct purchase of human cells 
and tissues. As the term ‘reasonable fee’ has not been defined, there is a grey zone and plenty room for 
misuse in terms of profit making from the processing of cells and tissues. In 2007, US Senator Charles 
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Schumer introduced the Safe Tissue Act, designed to ‘improve the oversight and regulation of tissue 
banks and the tissue donation process, and for other purposes’. The bill, if accepted, would determine 
the concept ‘reasonable processing fee.’ Up till now, the bill did not become law.  
 
 
To ensure availability and patients’ access  
The ultimate aim of the EUCTDs is to ensure the availability and patient’s access to HCT/Ps and there 
are no indications that it will not do that. But one must wonder, (i) which HCT/Ps will mainly become 
available – the highly profitable or the medically important? – and (ii) to whom will they be available 
– to everyone or only to those who can afford them? 
 
(i) Highly profitable or medically important? 
The interests of the general public, hospitals and corporate TEs are not always in line with each other 
and in certain cases they might be conflicting. Where hospitals mostly operate on a non-profit basis, 
focusing on medically important trajectories for health care, private TEs take a business approach to 
ensure their profits (for further investments and shareholders’ contributions), often taking a more 
lucrative approach with respect to the processing of donated cells or grafts. This is not because they 
are ‘bad.’ Under Anglo-American law, corporate managers have a strict fiduciary duty to act in the 
interest of share-holders13. Examples of profit-maximizing activities are the systematic processing of 
human donor skin, the golden standard in the management of severe burns14, into more lucrative 
products that can be used in plastic surgery or in vanity procedures such as penis-widening or lip 
enhancement in people with normal penis and lip sizes. More problematic is the possibility that some 
less lucrative, but life-saving, HCT/Ps will no longer be available. For example, in burn wound 
patients, the ideal replacement for missing skin is skin itself15. In the absence of sufficient amounts of 
autologous grafts (the patient’s own skin), human donor skin (from cadavers) is without any doubt the 
next best thing. To date, there are no biosynthetic skin replacements that provide the physical and 
physiological functions of human skin. The signs are already there that industrially prepared 
biosynthetic dressings will replace human donor skin for the temporary covering of burns. Indeed, 
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biosynthetic dressings are business as usual for pharmaceutical companies. They can be produced 
from widely available raw materials, which can be used in GMP production, and the resulting end 
products are standardized, well defined and – last but not least – can be adequately protected by 
patents. Human donor skin, as offered by conventional tissue banks, is a whole different ball game. 
The starting material is of variable ‘not standardized’ quality and inherently contaminated (at least 
with commensal bacteria) and the end product is also whimsical and – as ‘product of nature’ – difficult 
to protect by patents today.  
Till recently, HCT/Ps produced and used at hospitals and not processed on an industrial basis, hence 
not aimed to be placed on the global market, were not considered as medicinal products. Today, the 
implementation of the ATMP regulation seems to ruffle feathers in the whole HCT/P landscape, 
illustrated by the following example. Keratinocytes produced by the keratinocyte bank of the Queen 
Astrid Military Hospital in Brussels have been used as auto- and allografts in more than 1,000 
patients, primarily to accelerate the healing of burns and donor sites16. The keratinocyte bank has 
always been compliant with the relevant Belgian and European legislation. Since its creation in 1987, 
it is licensed upon inspection by the competent authority and since 2008, an ISO 9001 certified 
Quality Management System (QMS) governs all aspects of testing, processing, distribution, validation 
and traceability. Recently, the Committee for Advanced Therapies (CAT) of the European Medicines 
Agency (EMA) classified keratinocyte grafts as ATMPs. Full compliance with the ATMP regulation 
(without hospital exemption) would imply a dramatic increase in price for the hospital at stake to offer 
this therapy. First of all, even if there could be a possibility to get a much higher reimbursement price 
within the national health system, responsible health practitioners would feel that keratinocytes in burn 
wound surgery do not warrant such an unnecessary high price. It would be an uncomfortable situation. 
Besides the purely economical aspects, public cell and tissue banks, like the hospital ones, are not 
necessarily interested in general market placement, centralized marketing authorization or intellectual 
property (IP) protection. Finally, the change in GMP requests will not necessarily lead to a measurable 
improvement of the QS of the keratinocyte grafts. The numerous competent authority inspections at 
the hospital in the past 25 years never revealed the slightest health care risk. Conversely, for the 
industry, the potential market (severely burnt patients) is probably too small to consider. In practice, 
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this means that in the course of 2012 (end of the transitional period for somatic cell ATMPs in 
Belgium), keratinocyte therapy, which has shown its usefulness in the past, will probably no longer be 
available to the severely burnt patients in the burn wound centers in Belgium.  
 
(ii) Available to everyone? 
The development of HCT/Ps requests high investment costs if such products are aimed to be placed 
‘on the market’ because for ATMPs, stringent and long-lasting regulatory procedures need to be 
complied with. The reimbursement of medical costs differs from country to country. In Belgium, 
health care insurance is part of the social security system. Medical costs are reimbursed by a health 
insurance fund and reimbursement rates are fixed by the government. The reimbursement rates of 
‘conventional’ HCT/Ps are published in a ministerial decree that also fixes the price of lyophilization 
and WHO-approved prion- and virus-inactivation techniques. This price system for HCT/Ps is unique 
in the EU and was installed to cover the real costs of processing and to leave no room for unreasonable 
profits. In 2011, a Belgian stock market listed biomedical company received the notification by the 
Belgian Minister of Social Affairs of the approval of a convention agreement between the Belgian 
reimbursement authority for the reimbursement (for a period of three years) of ChondroCelect®, 
characterized autologous chondrocytes for the treatment of symptomatic knee cartilage lesions in 
well-indicated patients in specialized centers. Today, ChondroCelect® is not only the first cell-based 
product to have obtained centralized European Marketing Authorization from EMA, it is also the first 
ATMP to obtain a national reimbursement17.  
The reimbursement price (19,837 EUR for one application, without operation- and hospital costs) for 
ChondroCelect® is nearly ten times the price of conventional non-ATMP and non-EMA approved 
autologous chondrocyte cultures (2,117.29 EUR for one application) in Belgium. Due to the high 
costs, the reimbursement of the procedure will be restricted to patients younger than 50 years. 
The company’s clinical stage development pipeline includes an allogeneic stem cell product for the 
treatment of rheumatoid arthritis, a growing pharmaceutical market. 
The reimbursement of this first approved ATMP in Europe to only a part of the potential patients 
indicates that social security systems will probably not be able to cope with the cost of future ATMPs. 
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Who will then pay for these emerging therapies? The patients, whether or not through private 
insurances? When policy makers stated that the HCT/P legislation was installed to ensure patient’s 
access to HCT/Ps, probably they overlooked that not all patients could be served. Therefore, the 
industry and the reimbursement authorities should decide which ATMPs will warrant future 
reimbursement (for every needy patient) and this prior to their development, which is often co-funded 
with tax money (the EU and most National funding agencies prioritize health research in support of 
industry). Once the HCT/P is developed and approved, the pressure on the companies and the 
authorities to provide reimbursement becomes harmfully high. Biopharmaceuticals and biosimilars, 
other fast-growing segments of the pharmaceutical market, are also confronted with a risky, complex 
and expensive development process (from research to reimbursement). Simoens et al. suggested the 
early inclusion of health economics in the process of developing of biopharmaceuticals and 
biosimilars with a view to demonstrating their relative (cost) effectiveness and informing registration, 
pricing and reimbursement decisions18.  
 
One of the goals of the ATMP regulation was to ‘allow the highest level of health protection’. How 
does a decrease (in number and in variety) of conventional grafts with well-established medicinal use 
and an increase in sophisticated commercially interesting products that are only accessible to a limited 
part of the population fit into this? Industry as well as the non-profit sector must reconsider how health 




The ATMP regulation puts high demands on companies aiming at developing such products for the 
market. Several specialized processing techniques (e.g. cleanroom technology) have been introduced 
at the industrial level. However, there are some companies that also introduced (extensive) marketing 
techniques, unreasonable (strategic) patenting activities and advertising efforts into cell and tissue 
banking. Marketing and advertising are known to have the power to influence consumer (physicians) 
habits and perceptions positively, but unfortunately also negatively. For example, some biomedical 
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companies are known to promote the use of biosynthetic dressings. In (company driven) efficacy 
studies their product is compared with less efficient biosynthetic dressings at best19, never to the 
golden standard, human donor skin14.    
 
 
Towards a globalization of the HCT/P market? 
In 1983, Harvard Business School professor Theodore Levitt argued that companies should emphasize 
on offering standardized products all over the world20. Companies that concentrated on idiosyncratic 
consumer preferences would not be able to take in the forest because of the trees. As today’s 
successful global brands demonstrate, this notion clearly makes sense from a linear/mechanistic 
economical point of view. As most (if not all) markets, the emerging global HCT/P market is 
inherently confronted with financial considerations. The current HCT/P legislations exhibit loopholes 
that allow excessively free maneuvering of those that seek economic advantage, which is quite logic 
from an economical point of view. And was it not one of the goals of the ATMP regulation to ‘allow 
competitiveness in a key biotechnology area and growth of an emerging industry’? Unfortunately, 
often service to the public health is not seen as a key priority. In the 1970s, most capitalists embraced 
Milton Friedman’s view that the social responsibility of business is to increase its profits, not to relax 
the conditions of profit-maximization on behalf of the wider interests of society21. But, is this 
acceptable when it comes to healthcare? Surely, companies involved in the healthcare industry should 
live up to their responsibilities towards the public interest, not only towards their shareholders. To 
quote Bela Blasszauer: ‘medicine is a moral enterprise whether it is practiced in the system of slavery 
or market economy’22.  
Defenders of Friedman’s thesis claim that for executives to use company resources to advance social 
goals would be for them to usurp the political function13. In this context it might thus be up to the 
political world to demand healthcare companies to defy the laws of economics and fulfill social duties.  
 
 
Conventional cell and tissue banks are disappearing 
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The EC introduced industry standards for product development and marketing. However, these 
marketing activities often surpass their goals, in a field that was formerly dominated by altruistic 
hospital-based tissue banks. These banks are often not interested in the (global) marketing of their 
grafts and lack the regulatory experience and finances to implement the imposed requirements in due 
time. If the current evolutions in the field continue, in the near future European conventional cell and 
tissue banks will either throw in the towel or be reduced to facades (suppliers) for corporate TEs, 
especially where the cells and tissues are the basis for lucrative ATMPs.  
One cause of the increased regulatory oversights was that, in the past, some tissue banks were indeed 
nonchalant in dealing with QS. However, there is a need for a sense of proportion and to make sure 
that the baby is not thrown out with the bath water. In his keynote speech at the 6th World Congress of 
Tissue Banks, John Kearney explained that there is a need for public cell and tissue banks. They are, 
for example, far more efficient in the procurement of human tissues and turning them into natural 
matrices that can be re-populated by the patients’ own cells. The pharmaceutical industry, on the other 
hand, is far more efficient in the large-scale production of synthetic scaffolds and cell lines. It is key 
that public cell and tissue banks survive the introduction of expensive production and marketing 
requirements. A way for them to survive globalization could be to organize themselves in central 
tissue banks, which operate on a large scale, eventually partially sponsored by the government. 
We fear that the implementation of the EU HCT/P legislation will ultimately lead to a globalized 
market with corporate TEs that will produce only a limited number of uniform HCT/Ps.  
 
 
Comparison with the food sector 
There are striking parallels with the food sector. The rising liberalization of agro-industrial markets 
was also accompanied by technological advances and the introduction of an EU regulatory framework. 
In January 2006, the EU General Food Law entered into force, introducing General Principles like 
GMP, Good Agricultural Practices (GAP), Good Distribution Practices (GDP) and requirements for 
traceability, responsibility and withdrawal in the food sector. In addition, the EU Hygiene Package 
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introduced further requirements such as registration, labeling, documentation and self-inspection. 
Small food producers, unable or not willing to go along with technological advances and new 
ideologies in marketing, are suffering under the new product safety regulations. Established (some are 
around for centuries) and tasty local products are suddenly presumed of inferior QS and are gradually 
replaced by uniform pale global brands, with (a perception of) high QS. Bioengineering is rapidly 
transforming the crop development industry, accelerating the concentration and centralization of agro-
chemical corporations pushing (genetically modified) monocultures and undermining the cultural 
diversity of local farmers. Over the last decades, small independent beer brewers are diminishing in 
significance as brewing multinationals, resulting from mergers and (aggressive) acquisitions, have 
transformed one of the oldest industries in the world from a local market into a global one. Recently, 
the US artisan cheese world was shaken by the shutdown, by the US Federal Drug Agency (FDA), of 
several small (award-winning) cheese making facilities, due to bacteria findings in cheeses. Those 
defending the age-old methods of local craftsmen find the QS rules and inspections to be over the top 
and argue that the products of large-scale food companies have caused many more illnesses than any 
product from small producers. Of course, in the future some fine specialties will still be produced and 
globally distributed, according to the new requirements, as delicacies (e.g. French ‘Grand Cru’ wines) 
for people who can afford it.    
 
 
Respect for the donor 
A scene in the 1973 movie ‘Soylent Green’ comes to mind. In 2022, the natural resources have been 
exhausted and people are fed synthetic Soylent products (green crackers said to be made of plankton). 
Detective Thorn (Charlton Heston) steals a number of food items from the home of a wealthy murder 
victim. Although they used to be everyday foods like wine, apples and meat, his older friend Sol Roth, 
who remembers the time when tasty food was plenty, breaks down into tears at the thought of meat. At 
the end of the movie Thorn uncovers the disturbing truth about the real ingredients of Soylent Green, 
recycled human bodies. But, why was this discovery so disturbing and even appalling to viewers? In 
times of overpopulation, famine and no resources, human bodies do constitute a vital source of food. 
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Chimpanzees’ need to feed sometimes leads them to cannibalism. Moreover, in the movie, it surely 
looks like Soylent Green is produced according to high QS requirements. So, why should the optimum 
utilization of human bodies not be explored? Probably because our civilization, for centuries, accepts 
and demands respect for the dead23. Turning human bodies (in secret) into lucrative products for a 
global food (or pharmaceutical) industry would not be very respectful. Critics of markets in body parts 
state that they are ethically wrong because they violate a fundamental ethical norm that the body 
should not be treated either as a property or as a commodity9. Donor families expect HCT/Ps to be 
treated with respect and recognized as resulting from a donation from their loved ones24. Instead, 
tissues donated to tissue banks are increasingly processed into products with little or no resemblance 
to human tissue like cubes, screws, chips, paste, glue and powder, which are then sealed in appealing 
packaging and advertised in glossy catalogs as if they were commodities. Thorn’s final warning ‘Soon 




Quality and safety requirements 
Most incidents involving unsafe HCT/Ps were not the result of too loose QS requirements in 
legislations. They were due to the greed of opportunists that downright ignored the guidelines and 
common sense and engaged in profit-maximizing activities that ultimately endangered patients and 
trampled ethics. Importantly, these incidents are not representative of the entire tissue banking 
community. In Belgium, as in most EU Member States, the national pre-EUCTD human cell and 
tissue legislations and quality standards functioned well. They succeeded in safeguarding the provision 
of acceptable amounts of affordable, safe and ethically sound HCT/Ps.  
There is no doubt that the implementation of the EU HCT/P legislation will increase overall QS to the 
HCT/P field. However, we have to keep in mind that QS is no fairy dust or magic formula. A false 
perception of QS is creeping in. For example, recently, the French authorities issued a guideline 
urging 30,000 French women to have their breast implants removed25. A French company was found 
to be cutting corners by making breast implants from cheaper industrial-grade silicone normally used 
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for electronics, mattresses or the agriculture industry. In addition, these implants have a relatively high 
chance of bursting. And yet, they were granted a certificate of conformity with European standards 
and hundreds of thousands of them were sold on three continents. 
How do regulations see to improve the measurable benefits to patient care and safety, taking into 
account the considerable burdens on service providers and businesses, and ultimately the community 
as a whole26? In some cases, the substantial increase in requirements introduced by the EUCTDs and 
the ATMP regulation result in a massive increase in costs (material and personnel), without 
measurable gain in QS.  
Unfortunately, today, HCT/Ps seem to be regulated through manufacturing assessment and any issues 
of therapeutic efficacy or benefit to the patient are side-stepped7. What does the concept ‘Quality and 
Safety’ really mean? According to ‘WHO Europe’ guidance, ‘a quality health service is one which 
organizes resources in the most effective way to meet the health needs of those most in need, for 
prevention and care, safely, without waste and within higher level requirements’. It is our feeling that 
when it comes to the EUCTDs, policy makers limited the definition of QS to ‘safe and within higher 
level requirements.’ Strangely, ‘quality’ and ‘safety’ are always pronounced in one breath and seem to 
be reduced to synonyms. In addition, we get the feeling that ‘safe’ almost exclusively means ‘free of 
transmissible diseases.’ There is nothing in the EUCTDs that prescribes that prepared HCT/Ps must be 
of high quality and safe in a sense of achieving the intended clinical utility. For example, commercial 
autologous cord blood banks are emerging worldwide. Some of them take advantage of the 
vulnerability and ignorance of new parents to urge them to store the cord blood for ‘possible’ future 
clinical use in their child, its siblings or family members. For this service they charge handsome fees 
(2,395 EUR in Belgium). There are, however, no indications that these autologous stem cells will be 
more effective than allogeneic stem cells stored in public cord banks and are accessible to all patients 
in need27.  
In our opinion, the safest HCT/P is not necessarily the most qualitative or the most effective way to 
meet health needs of those most in need. There is a point at which legislation can actually compromise 
patient care and safety, by hindering valuable established therapies or delaying the development of 
new technologies. Efficacy should not be sacrificed in the name of QS. In the end, what saves more 
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severely burnt patients’ lives, conventional human donor skin with an infinite small risk of disease 
transmission or sterile biosynthetic dressings? According to the current generation of surgeons in the 
burn wound center of the Military Hospital, without any doubt, the former.      
In addition, the EUCTD QS requirements are generic (not tailored to specific HCT/Ps). As such, they 
apply to heart valves as well as to skin. Heart valves are sterile at the time of harvesting and will be 
grafted internally during an aseptic surgical procedure in an operating theatre. Skin, in contrast, is 
inhabited with micro-organisms (commensals), which out-compete potentially harmful bacteria and 
prevent them from inhabiting the skin surface. In addition, the skin of donors is in contact with the 
(uncontrolled) environment during the entire life of the donor. Upon death, the non-heart beating skin 
donor is kept in a fridge in the mortuary for many hours before skin procurement takes place. The 
harvested donor skin is applied in a hydrotherapy facility, a room in the one-day clinic or an operating 
theatre at best, where it is grafted on the surface of non-sterile and often infected burn wounds next to 
the patient’s intact skin that is colonized with commensals. Yet, the same arbitrary clean room air 
quality requirements for tissue processing (which only takes a few hours), should be applied to heart 
valves and skin alike. For IVF laboratories, these air quality requirements will not only have a 
negligible impact on QS, they will probably compromise the ability to maintain gametes and embryos 
under optimum environmental conditions. 
While some QS requirements are based on objective evidence, others seem to have been whispered by 
the precautionary principle, a key paradigm of current regulatory thinking. This principle can be 
expressed as: ‘complete evidence of risk does not have to exist to institute measures to protect 
individuals and society from that risk.’ According to Kirkland26, we should try to balance the risk 
avoidance principles with the broader risks to the community that can result from overzealous or 
inappropriate application of regulatory standards (e.g. consider the access to life-saving therapies with 
a certain risk of disease transmission). This can only happen if the application of these regulations is 
flexible, adaptable and subject to review. Within an EC co-funded project, rational and tissue specific 
European Good Tissue Practices (EuroGTPs) are being developed. It is not sure whether these 





Bone donations to a Bulgarian tissue bank are sent to a TE in New Jersey USA for processing. The 
finished products are sent to TEs in more than 20 countries in 4 continents, including a TE in France. 
In 2008, a joint inspection was conducted by AFSSAPS, the French competent authority, and the 
Bulgarian Executive Agency. The inspection highlighted one critical and 10 major deficiencies that 
were not in compliance with the EUCTDs. These deficiencies were related to procurement activities. 
There were serious concerns regarding traceability and validity of blood sample labeling and donor 
records. AFSSAPS requested the recall of bone products supplied by the French TE11.  
Unfortunately, such thorough cross-border and human cell and tissue procurement site inspections are 
only rarely performed. In addition, competent authorities’ inspectors often lack the guidance, training 
(e.g. collected evidence must be relevant for use in court) and power (compared to police) to swiftly 
and efficiently act against Illegal or Fraudulent Activity (IFA) as it is called today. The enforcement of 
the EU HCT/P legislation should become more efficient. Therefore, in March 2010, the EU-funded 
project ‘Vigilance and surveillance of substances of human origin’ (SOHO V&S) was launched.  
Obviously, the increasing number of Legal Excessive Profit-making Activities (LEPRAs) cannot be 
countered by more efficient and more frequent inspections. Limiting the profit that can be made on the 




Discussion and conclusions 
In 1985, author and philosopher Malcolm Muggeridge warned in his key note address at an 
international symposium on organs and transplantation held at Lake Louise (Canada) that the ‘hacking 
out of bits of peoples organs and putting them on the market is becoming an extraordinarily lucrative 
occupation. It’s going to be a very big trade’ and ‘where you have money being the decisive factor, 
there you will have trouble and disruption inevitably’23. More than a quarter of a century later the 
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‘declaration of Istanbul on organ trafficking and transplant tourism’ urges EU Member States ‘to take 
measures to protect the poorest and vulnerable groups for transplant tourism and the sale of tissues and 
organs, including attention to the wider problem of international trafficking in human tissues and 
organs’28. Today, Malcolm Muggeridge’s forecast has thus come true as a gradual model of 
commercialization and commodification of human cells and tissues can be observed, also in Europe, 
where healthcare is increasingly governed by EU legislation. The EUCTDs are enacted through 
common QS standards and evade public debate because they are merely seen as ‘technical matters’29.  
Yet, the implementations of the EUCTDs that appear to be necessary to policy makers, while at the 
same time remaining somewhat disconnected from the everyday reality of cell and tissue bankers, hold 
serious dangers, which need to be urgently addressed. 
The current EU HCT/P regulatory framework allows for-profit TEs and facilitates the development of 
a uniform global HCT/P market, and is not able to deal with the technological innovation and 
controversial market-driven practices that raise deep ethical issues today.   
As a result, the most profitable HCT/Ps are the ones that are most likely to be developed in the interest 
of shareholders, which takes precedence over the public interests. In addition, it is questionable 
whether the health care and social security systems of EU Member States will be able to cope with the 
rising health care costs entailed by increasingly stringent QS requirements.  
Why is the regulatory framework not able to curb this? First of all, ethical issues (e.g. allocation rules) 
could not be addressed as the EC was not mandated by the Maastricht Treaty (that lead to the creation 
of the European Union) to do so. For organs, allocation issues have been addressed by a number of 
not-for-profit service organizations like Eurotransplant International Foundation, Scandiatransplant, 
and the National Health Service Blood and Transplant in the UK.  
Secondly, while there were numerous concerns in the cell and tissue banking world (e.g. LEPRAs 
were already emerging), the minimization of infectious disease risk turned out to be the paramount 
driver for the introduction of more regulation in this field.  
Finally, Christian Lenk and Katharina Beier recently argued that the ban on commercialization of 
body material is not as strict as it may appear at first sight, leaving room for commercial practice of 
tissue procurement and transfer30. On the one hand EU policy makers claim they wish to avoid the 
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commercialization of HCT/Ps, but on the other hand they are apparently very reluctant to put this into 
hard (binding) wording. According to Faulkner et al., the EUCTD was created through a democratic 
process and professional trade associations such as EUCOMED and EuropaBio lobbied extensively on 
this regulation31. It is logic for a business to ward off profit-reducing regulation. Public altruistic cell 
and tissue banks simply lacked organization, power and experience to lobby relevant EU legislation.  
There are, however, extenuating circumstances. When the EU HCT/P legislation was developed, in the 
late 90s - early 2000s, the HCT/P transplantation field was in its infancy. But, it rapidly grew from a 
‘cottage industry’ of small non-profit and predominantly hospital-based surgical banks, which 
provided minimally processed tissues to local surgeons, to a booming industry in which highly 
sophisticated HCT/Ps are distributed worldwide. The field has become much more complex, with 
technical advances and extensive commercialization, than the policy makers and experts expected 
when they started elaborating the EUCTDs. In addition, there are indications that key aspects of 
European policies designed to protect public health were undermined in a generic way by certain 
players in the field. Recently, it was demonstrated that from 1995 an alliance of corporate actors 
actively worked to successfully promote a business-oriented form of Impact Assessment (IA) of all 
major EU policies32. This increases the likelihood that the EU produces policies that advance the 
interests of major corporations, including those that produce products damaging health, rather than in 
the interest of its citizens. A health-oriented IA involving all stakeholders would have been more 
appropriate in assessing public health policies. 
It’s about time for a comprehensive review and revision of the EU HCT/P regulation. This poses an 
acute policy maker’s dilemma. Some feel that the commercialization and commodification of HCT/Ps 
should be restricted, in the name of the overall public health framework, including patients and donor 
families. On the other hand, pharmaceutical and biomedical companies are no charitable 
organizations; their goal is to maximize shareholders’ profits. Should the European biotechnology be 
denied a commercial opportunity? Politicians are not immune to these tensions.  
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Cynics believe that the commercialization of all aspects of society is inevitable and resistance futile. 
However, if EU policy makers decide to give priority to the overall public interest and halt the erosion 
of public healthcare systems, they should update the HCT/P legislation to: 
• prioritize the solidarity principle of public TEs;  
• prioritize medically relevant HCT/Ps;  
• introduce cell or tissue specific QS requirements based on common sense and objective 
evidence;  
• control HCT/P prices through a regulatory mechanism; 
• introduce fair, transparent and binding exportation rules with an emphasis on self-sufficiency; 
• be enforced by efficient (cross border) inspections. 
 
On the other hand, if the globalization of the healthcare industry is part of a political philosophy and 
EU policy makers decide to continue on the route of HCT/P commercialization, they should clearly 
speak their mind. Under the pretext of food safety, legislation facilitated the concentration, or even 
globalization, of the food supply. Is the HCT/P transplantation field about to drift in the same 
direction? Are QS requirements like GMP becoming selection pressures for HCT/Ps?  
 
In an interview with the New York Times Theodore Malinin of the University of Miami Tissue Bank 
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